August 21, 2020 10:33 AM EDT

Lilly Asia Ventures leads AstraZeneca spinout's $100M push into China's growing R&D hub in Wuxi

Amber Tong

Senior Editor

Three years after launching with three preclinical assets from AstraZeneca’s R&D center in Shanghai and $132.5 million in cash, Dizal Pharma has drawn marquee new investors in for a $100 million reload.

Under CEO Xiaolin Zhang, the team — most of whom transitioned from AstraZeneca’s (now-defunct) Innovation Center China — has shepherded the lead asset into the clinic for non-small cell lung cancer and an unnamed autoimmune disease. INDs for a second cancer drug are in and three others are on close on its heels, with a final chronic kidney disease drug partnered with AstraZeneca tugged at the bottom of the pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Lilly Asia Ventures leads AstraZeneca spinout's $100M push into China's growing R&D hub in Wuxi

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Bruker to acquire troubled spatial biology company NanoString for $392M

Lil­ly Asia Ven­tures leads As­traZeneca spin­out's $100M push in­to Chi­na's grow­ing R&D hub in Wuxi

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Bruk­er to ac­quire trou­bled spa­tial bi­ol­o­gy com­pa­ny NanoS­tring for $392M

Lilly Asia Ventures leads AstraZeneca spinout's $100M push into China's growing R&D hub in Wuxi

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Bruker to acquire troubled spatial biology company NanoString for $392M